Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 Monetary Arranging Administrations for Your Necessities - 2Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- 3Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 4US EPA will reassess safety of herbicide paraquat, says its chief
- 5Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- 10 Famous Frozen yogurt Flavors All over The Planet
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime
- Apartment Turned Into Nightmare 'Ice Castle' After Tenant Shut Off Heat Causing Pipes to Burst: VIDEO
